HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Viberg, A. Articles by Jönsson, S. Search for Related Content PubMed PubMed Citation Articles by Viberg, A. Articles by Jönsson, S. Social Bookmarking                         What's this?

Estimation of Cefuroxime Dosage Using Pharmacodynamic Targets, MIC Distributions, and Minimization of a Risk Function

From the Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (Dr Viberg, Dr Karlsson, Dr Jönsson), and the Department of Medical Sciences, Infectious Disease, Uppsala University Hospital, Uppsala, Sweden (Dr Cars).

An approach for estimation of dosing strategies based on data-derived models and assessment of the risk associated with deviation from the treatment target is presented. The work is illustrated by establishing a dosing strategy to be used for a priori individualization on the basis of renal function for the antibiotic cefuroxime. Treatment involved exposing patients to concentrations above the minimum inhibitory concentration (MIC) for 50% of the dosing interval. The risk (penalty) function incorporated both deviations from the target and the use of excess amount of drug. Dosing strategies were estimated for a target population by minimizing the risk function. The population was characterized by a population pharmacokinetic model, and distributions of CLcr and body weight were reflective of the target group. The estimated dosing strategies were assessed by evaluating population distributions of (1) percentage of dosing interval with concentrations above MIC, (2) time of drug exposure below MIC, and (3) drug administered in excess to reach the target. These distributions were generated using wild-type MIC distributions for Escherichia coli and Streptococcus pneumoniae. The authors illustrate how benefits and risks of drug treatment can be weighed quantitatively in decision-based risk functions and subsequently used in the estimation of drug dosing.

Key Words: Cefuroxime • dosing strategy • individualization • MIC • risk function

Address for reprints: Anders Viberg, PhD, AstraZeneca R&D Södertälje, Clinical Pharmacology & DMPK, SE-151 85 Södertälje, Sweden.; e-mail: anders.viberg{at}astrazeneca.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. B. Bulitta, C. B. Landersdorfer, M. Kinzig, U. Holzgrabe, and F. Sorgel New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3462 - 3471. [Abstract] [Full Text] [PDF]